Chronic granulomatous disease (CGD) and complete myeloperoxidase deficiency both yield strongly reduced dihydrorhodamine 123 test signals but can be easily discerned in routine testing for CGD

Clinical Chemistry

Volumn 53, Issue 5, 2007, Pages 890-896

  Mauch, Lysann ^a   Lun, Andreas ^b   O'Gorman, Maurice R G ^c   Harris, John S ^d   Schulze, Ilka ^e   Zychlinsky, Arturo ^f   Fuchs, Tobias ^f   Oelschlägel, Uta ^g   Brenner, Sebastian ^a   Kutter, Dolphe ^h   Rösen Wolff, Angela ^a   Roesler, Joachim ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b Universittsklinikum Charit   (Germany)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d Valley Medical Center   (United States)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^h Laboratoires Reunis Kutter Lieners Hastert Centre Langwies   (Luxembourg)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDRORHODAMINE 123; LUCIGENIN; MYELOPEROXIDASE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE;

ARTICLE; CELL STRAIN K 562; CHRONIC GRANULOMATOUS DISEASE; CLINICAL ARTICLE; ENZYME ACTIVITY; ENZYME DEFICIENCY; EOSINOPHIL; FALSE POSITIVE RESULT; FEMALE; HUMAN; HUMAN CELL; MALE; MYELOPEROXIDASE DEFICIENCY; NEUTROPHIL;

ACRIDINES; CHEMILUMINESCENT MEASUREMENTS; COLORING AGENTS; DIAGNOSIS, DIFFERENTIAL; EOSINOPHILS; FALSE POSITIVE REACTIONS; FEMALE; FLOW CYTOMETRY; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; K562 CELLS; LUMINESCENT AGENTS; MALE; NADPH OXIDASE; NEUTROPHILS; PEROXIDASE; RECOMBINANT PROTEINS; RHODAMINES; TRANSFECTION;

EID: 34248342558     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2006.083444     Document Type: Article

References (39)

1. Notarangelo L, Casanova JL, Conley ME, Chapel H, Fischer A, Puck J, et al. Primary immunodeficiency diseases: an update from the International Union of Immunological Societies Primary Immunodeficiency Diseases Classification Committee Meeting in Budapest, 2005. J Allergy Clin Immunol 2006;117:883-96.
2. Rothe G, Oser A, Valet G. Dihydrorhodamine 123: a new flow cytometric indicator for respiratory burst activity in neutrophil granulocytes. Naturwissenschaften 1988;75:354-5.
3. Roesler J, Hecht M, Freihorst J, Lohmann-Matthes ML, Emmendorffer A. Diagnosis of chronic granulomatous disease and of its mode of inheritance by dihydrorhodamine 123 and flow microcytofluorometry. Eur J Pediatr 1991;150:161-5.
4. Emmendorffer A, Hecht M, Lohmann-Matthes ML, Roesler J. A fast and easy method to determine the production of reactive oxygen intermediates by human and murine phagocytes using dihydrorhodamine 123. J Immunol Methods 1990;131:269-75.
5. Vowells SJ, Fleisher TA, Malech HL. Testing for chronic granulomatous disease. Lancet 1996;347:1048-9.
6. Roesler J, Emmendorffer A. Diagnosis of chronic granulomatous disease. Blood 1991;78:1387-9.
7. Vowells SJ, Sekhsaria S, Malech HL, Shalit M, Fleisher TA. Flow cytometric analysis of the granulocyte respiratory burst: a comparison study of fluorescent probes. J Immunol Methods 1995;178:89-97.
8. van Pelt LJ, van Zwieten R, Weening RS, Roos D, Verhoeven AJ, Bolscher BG. Limitations on the use of dihydrorhodamine 123 for flow cytometric analysis of the neutrophil respiratory burst. J Immunol Methods 1996;191:187-96.
9. Emmendorffer A, Lohmann-Matthes ML, Roesler J. Kinetics of transfused neutrophils in peripheral blood and BAL fluid of a patient with variant X-linked chronic granulomatous disease. Eur J Haematol 1991;47:246-52.
10. Jirapongsananuruk O, Malech HL, Kuhns DB, Niemela JE, Brown MR, Anderson-Cohen M, et al. Diagnostic paradigm for evaluation of male patients with chronic granulomatous disease, based on the dihydrorhodamine 123 assay. J Allergy Clin Immunol 2003;111:374-9.
11. Rupec RA, Petropoulou T, Belohradsky BH, Walchner M, Liese JG, Plewing G, et al. Lupus erythematosus tumidus and chronic discoid lupus erythematosus in carriers of X-linked chronic granulomatous disease. Eur J Dermatol 2000;10;184-9.
12. Crockard AD, Thompson JM, Boyd NA, Haughton DJ, McCluskey DR, Turner CP. Diagnosis and carrier detection of chronic granulomatous disease in five families by flow cytometry. Int Arch Allergy Immunol 1997;114:144-52.
13. Atkinson TP, Bonitatibus GM, Berkow RL. Chronic granulomatous disease in two children with recurrent infections: family studies using dihydrorhodamine-based flow cytometry. J Pediatr 1997;130:488-91.
14. Koker MY, Sanal O, de Boer M, Tezcan I, Metin A, Tan C, et al. Skewing of X-chromosome inactivation in three generations of carriers with X-linked chronic granulomatous disease within one family. Eur J Clin Invest 2006;36:257-64.
15. Lun A, Roesler J, Renz H. Unusual late onset of X-linked chronic granulomatous disease in an adult woman after unsuspicious childhood. Clin Chem 2002;48:780-1.
16. Rosen-Wolff A, Soldan W, Heyne K, Bickhardt J, Gahr M, Roesler J. Increased susceptibility of a carrier of X-linked chronic granulomatous disease (CGD) to Aspergillus fumigatus infection associated with age-related skewing of lyonization. Ann Hematol 2001;80:113-5.
17. Anderson-Cohen M, Holland SM, Kuhns DB, Fleisher TA, Ding L, Brenner S, et al. Severe phenotype of chronic granulomatous disease presenting in a female with a de novo mutation in gp91-phox and a non familial, extremely skewed X chromosome inactivation. Clin Immunol 2003;109:308-17.
18. Rump A, Rosen-Wolff A, Gahr M, Seidenberg J, Roos C, Walter L, et al. A splice-supporting intronic mutation in the last bp position of a cryptic exon within intron 6 of the CYBB gene induces its incorporation into the mRNA causing chronic granulomatous disease (CGD). Gene 2006;371:174-81.
19. Mardiney M III, Jackson SH, Spratt SK, Li F, Holland SM, Malech HL. Enhanced host defense after gene transfer in the murine p47phox-deficient model of chronic granulomatous disease. Blood 1997;89:2268-75.
20. Ott MG, Schmidt M, Schwarzwaelder K, Stein S, Siler U, Koehl U, et al. Correction of X-linked chronic granulomatous disease by gene therapy, augmented by insertidnal activation of MDS1-EVI1, PRDM16 or SETBP1. Nat Med 2006;12:401-9.
21. Malech HL, Maples PB, Whiting-Theobald N, Linton GF, Sekhsaria S, Vowells SJ, et al. Prolonged production of NADPH oxidase-corrected granulocytes after gene therapy of chronic granulomatous disease. Proc Natl Acad Sci U S A 1997;94:12133-8.
22. Emmendorffer A, Nakamura M, Rothe G, Spiekermann K, Lohmann-Matthes ML, Roesler J. Evaluation of flow cytometric methods for diagnosis of chronic granulomatous disease variants under routine laboratory conditions. Cytometry 1994;18:147-55.
23. O'Gorman MR, Cdrrochano V. Rapid whole-blood flow cytometry assay for diagnosis of chronic granulomatous disease. Clin Diagn Lab Immunol 1995;2:227-32.
24. Roesler J, Koch A, Porksen G, von Bernuth H, Brenner S, Hahn G, et al. Benefit assessment of preventive medical check-ups in patients suffering from chronic granulomatous disease (CGD). J Eval Clin Pract 2005;11:513-21.
25. Van den Bossche J, Devreese K, Malfait R, Van de Vyvere M, Wauters A, Neeis H, et al. Reference intervals for a complete blood count determined on different automated haematology analysers: Abx Pentra 120 Retic, Coulter Gen-S, Sysmex SE 9500, Abbott Cell Dyn 4000 and Bayer Advia 120. Clin Chem Lab Med 2002;40:69-73.
26. Fujinami N, Sugimoto Y, Hagiwara A. Induction of erythroid maturation by dimethyl sulfoxide in friend leukemic cells. Dev Growth Differ 1973;15:141-51.
27. Roesler J, Heyden S, Burdelski M, Schafer H, Kreth HW, Lehmann R, et al. Uncommon missense and splice mutations and resulting biochemical phenotypes in German patients with X-linked chronic granulomatous disease. Exp Hematol 1999;27:505-11.
28. Marchetti C, Patriarca P, Solero GP, Baralle FE, Romano M. Genetic characterization of myeloperoxidase deficiency in Italy. Hum Mutat 2004;23:496-505.
29. Nauseef WM, Cogley M, McCormick S. Effect of the R569W missense mutation on the biosynthesis of myeloperoxidase. J Biol Chem 1996;271:9546-9.
30. Nauseef WM, Brigham S, Cogley M. Hereditary myeloperoxidase deficiency due to a missense mutation of arginine 569 to tryptophan. J Biol Chem 1994;269:1212-6.
31. de M, I, Leto TL. Functional reconstitution of the phagocyte NADPH oxidase by transfection of its multiple components in a heterologous system. Blood 1995;85:1104-10.
32. Suzuki K, Muso E, Nauseef WM. Contribution of peroxidases in host-defense, diseases and cellular functions. Jpn J Infect Dis 2004;57:S1-2.
33. Kutter D. Inborn metabolic errors of white blood cells: myeloperoxidase deficiency of neutrophils and monocytes physiopathological consequences. Klinicka Biochemie Metabolismus 2003;11:141-7.
34. Cale CM, Jones AM, Goldblatt D. Follow up of patients with chronic granulomatous disease diagnosed since 1990. Clin Exp Immunol 2000;120:351-5.
35. Weening RS, de Boer M, Kuijpers TW, Neefjes VM, Hack WW, Roos D. Point mutations in the promoter region of the CYBB gene leading to mild chronic granulomatous disease. Clin Exp Immunol 2000;122:410-7.
36. Woodman RC, Newburger PE, Anklesaria P, Erickson RW, Rae J, Cohen MS, et al. A new X-linked variant of chronic granulomatous disease characterized by the existence of a normal clone of respiratory burst-competent phagocytic cells. Blood 1995;85:231-41.
37. Klebanoff SJ. Myeloperoxidase. Proc Assoc Am Physicians 1999;111:383-9.
38. Aniansson H, Stendahl O, Dahlgren C. Comparison between luminol- and lucigenin-dependent chemiluminescence of polymorphonuclear leukocytes. Acta Pathol Microbiol Immunol Scand [C] 1984;92:357-61.
39. Crow JP. Dichlorodihydrofluorescein and dihydrorhodamine 123 are sensitive indicators of peroxynitrite in vitro: implications for intracellular measurement of reactive nitrogen and oxygen species. Nitric Oxide 1997;1:145-57.